IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

• Maria Cristina Pirosa,
• Marianna Sassone,
• Barbara Kiesewetter,
• Armando Lopez Guillermo,
• Liliana Devizzi,
• Eva Domingo Domènech,
• Alessandra Tucci,
• Donato Mannina,
• Michele Merli,
• Antonio Salar,
• Carlo Visco,
• Fabiana Esposito,
• Luisella Bonomini,
• Emanuele Zucca,
• Andrés J. M. Ferreri,
• Markus Raderer

Affiliations

Maria Cristina Pirosa

Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona

Marianna Sassone

Lymphoma Unit,Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan

Barbara Kiesewetter

Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna

Armando Lopez Guillermo

Department of Hematology, Hospital Clínic de Barcelona, Barcelona

Liliana Devizzi

Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan

Eva Domingo Domènech

Department of Hematology, Institut Català d’Oncologia, Hospital Duran i Reynals, IDIBELL, Barcelona

Alessandra Tucci

Division of Hematology, AO Spedali Civili di Brescia, Brescia

Donato Mannina

Hematology Unit, AO Papardo, Messina

Michele Merli

Department of Haematology Ospedale di Circolo di Varese, Varese

Antonio Salar

Department of Clinical Hematology Hospital del Mar, Barcelona

Carlo Visco

Department of Medicine, Section of Hematology, University of Verona, Verona

Fabiana Esposito

Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona

Luisella Bonomini

Institute of Oncology Research, Bellinzona

Emanuele Zucca

Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona

Andrés J. M. Ferreri

Lymphoma Unit,Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan

Markus Raderer

Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna